CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

Oct  2021

Jadeite Medicines Inc. (“Jadeite”), a biopharmaceutical company that is backed by Singapore’s CBC Group (“CBC”) and committed to addressing critical unmet medical needs for patients in Japan, today entered into an exclusive licensing agreement with Albireo Pharma, Inc. (Nasdaq: ALBO) for the development and commercialization of odevixibat in Japan for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and biliary atresia.

READ MORE >

Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board

Sep  2021

RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA) platform company in Singapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the top international pioneers in RNA biology, Dr. Drew Weissman, M.D., Ph.D., has joined its science advisory board (SAB).

READ MORE >

Deal focus: NiKang pursues hard-to-drug targets

Jun  2021

With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKangTherapeutics is the first to secure wider investor attention

READ MORE >

NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

May  2021

Bing Yao, Ph.D., former chief executive officer and chairman of Viela Bio, and Ting Jia, Ph.D., founder, and chief investment officer of Octagon Capital Advisors to join NiKang’s Board of Directors

READ MORE >

Adcentrx Therapeutics Announces Completion of $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development

Apr  2021

NEWS PROVIDED BY CBC Group Apr 28, 2021, 19:30 ET

READ MORE >

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

Apr  2021

NEWS PROVIDED BY I-Mab Dec 01, 2020, 08:00 ET

READ MORE >

AbbVie puts $2B on the table for I-Mab cancer collab as biotech nabs $418M raise

Apr  2021

by Ben Adams | Sep 4, 2020 8:30am

READ MORE >

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium

Apr  2021

Ordinary Share Purchase price equivalent to $33.00 per ADS, at a premium to the 30-day volume weighted average price ("VWAP") Demonstrates leading biotech investors' strong endorsement of I-Mab's R&D innovation and value generation capabilities.

READ MORE >

I-Mab Added to Nasdaq Biotechnology Index

Apr  2021

- Global biotech index widely followed and tracked by investors and ETFs - IMAB added to the index upon first annual review since IPO - To be effective prior to the U.S. market open on Monday, December 21, 2020

READ MORE >

AffaMed Therapeutics Announces Merger with EverInsight Therapeutics and Appoints Dayao Zhao, M.D., Ph.D. as CEO

Apr  2021

Combined company led by Dr. Zhao creates robust and potentially first-in-class pipeline of drug candidates in growing ophthalmology and CNS markets

READ MORE >

Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China

Apr  2021

- US$100 million in milestone payments including US$20 million upfront, as well as a double-digit royalty - Nuance's business model, commercial acumen and collaborative approach considered an ideal fit for Antibe

READ MORE >

Nuance Pharma Closes Series D Financing

Apr  2021

Funds will support ongoing research & development and further business development

READ MORE >

VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

Jun  2020

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety

READ MORE >

Everest Medicines Completes US$310 Million Series C Financing

Jun  2020

Funds will support ongoing clinical development and preparations for potential commercialization

READ MORE >

Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti- Viral Diseases in China

Apr  2020

NiKang is eligible to receive an upfront collaboration fee and milestone payments of more than $100 million plus royalties on future net product sales

READ MORE >

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections

Apr  2020

HSA’s positive decision marks Everest Medicines’ rst-ever regulatory approval among robust pipeline of therapeutic candidates in development

READ MORE >

Ascletis Receives IND Approval for its HIV Drug ASC09F

Apr  2020

Ascletis Pharma Inc. announces today that it received IND approval from National Medical Products Administration for its human immunodeficiency virus (HIV) protease inhibitor ASC09F

READ MORE >

CMAB Biopharma Resumes Full-Scale Operation Following the Coronavirus Disease 2019 (COVID-19) Outbreak

Mar  2020

CMAB Biopharma (Suzhou) Inc. ("CMAB"), has continued to monitor the development of the COVID-19 pandemic and has taken proactive measures to primarily protect the health of our employees worldwide

READ MORE >

Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO

Mar  2020

Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deciency1,2

READ MORE >

Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer

Feb  2020

New CEO brings deep experience and expertise to lead company into next phase of growth as it continues to develop therapies for critical unmet needs in Greater China

READ MORE >

I-MAB Announces Pricing of U.S. Initial Public Offering

Jan  2020

ADSs to Begin Trading on Nasdaq on January 17, 2020

READ MORE >

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

Jan  2020

I-Mab Biopharma ("I-Mab"), a global biopharmaceutical company based in China and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology

READ MORE >

Everest Medicines Announces Approval of Nefecon’s Clinical Trial Application by the China National Medical Products Administration

Dec  2019

Everest Medicines entered into a license agreement with Calliditas Therapeutics to develop and commercialize Nefecon in June 2019

READ MORE >

AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901

Dec  2019

AMT901/SB3 is an intravenous trastuzumab for the treatment of HER2-positive breast cancer

READ MORE >

CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

Dec  2019

The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB

READ MORE >

Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

Nov  2019

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products

READ MORE >

CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership

Oct  2019

The new partnership will combine the research and development ingenuity of BJ Bioscience with the state-of-art biologics manufacturing set up of CMAB

READ MORE >

Everest Medicines Expands Senior Leadership Team

Sep  2019

Dr. Jason Brown becomes Chief Business Ocer. Dr. Frank Grams as Senior Vice President of Alliance Management and Head of Business Development in Europe

READ MORE >

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Jun  2019

Deal valued at a total of USD 121M plus royalty payments

READ MORE >

CMAB Biopharma Announces Dr. Wang Yongzhong as CEO to Strengthen Leadership and Continue Business Expansion

May  2019

(CMAB), a strict "pure-play" contract development and manufacturing organization (CDMO) focusing solely on services from sequence to commercial manufacturing for biologic products

READ MORE >

Everest Medicines Appoints Wende Chen as Chief Commercial Ocer

May  2019

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products

READ MORE >

Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

Apr  2019

The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop

READ MORE >

Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men

Mar  2019

JATENZO is a rst-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men

READ MORE >

CMAB Biopharma Secures $34 Million Series B Financing

Apr  2018

CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products

READ MORE >